HC Wainwright Forecasts Stronger Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a note issued to investors on Monday, July 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.29) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.10) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $0.77 EPS.

Several other equities research analysts have also recently commented on PYXS. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners cut their target price on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, July 2nd. Weiss Ratings lowered Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wedbush initiated coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Stifel Nicolaus reduced their target price on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, March 24th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.86.

Pyxis Oncology Trading Up 24.8%

Shares of NASDAQ PYXS opened at $3.07 on Wednesday. The stock has a market cap of $194.48 million, a PE ratio of -2.34 and a beta of 1.30. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55. The company has a 50-day moving average of $2.09 and a 200 day moving average of $1.71.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02).

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. Maia Wealth LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at about $25,000. Engineers Gate Manager LP acquired a new stake in shares of Pyxis Oncology during the fourth quarter valued at about $26,000. Fox Run Management L.L.C. purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $26,000. Avanza Fonder AB acquired a new position in shares of Pyxis Oncology in the 4th quarter worth approximately $31,000. Finally, XTX Topco Ltd acquired a new position in shares of Pyxis Oncology in the 2nd quarter worth approximately $40,000. 39.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Pyxis Oncology and reiterated a $7.00 price target, signaling continued upside potential despite recent estimate cuts.
• Neutral Sentiment: The analyst updated multiple longer-term forecasts, including improving its FY2030 EPS estimate to $0.77 from $0.99 previously, while still modeling the company as profitable later in the decade.
• Negative Sentiment: HC Wainwright lowered earnings expectations for several near- and medium-term periods, including FY2026 to ($1.10), FY2027 to ($0.88), and quarterly estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which points to a longer path to profitability. Article Title

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.